Advertisement
CRSP vs MRNA
Which Stock Would AI Choose? CRISPR Therapeutics (CRSP) vs. Moderna (MRNA) Stock Comparison
Key Takeaways
- CRISPR Therapeutics (CRSP) specializes in CRISPR-based gene editing for genetic disorders, while Moderna (MRNA) develops mRNA technology primarily for vaccines and oncology.
- In recent market activity, CRSP has shown downward pressure with prices near $46-47 amid broader biotech sector challenges, contrasting with MRNA’s strong year-to-date gains exceeding 80% despite recent volatility.
- Both companies operate in the biotechnology sector with high research and development expenses and pipeline-dependent valuations, exposing them to clinical and regulatory risks.
- Analyst sentiment remains constructive for CRSP with elevated price targets, while MRNA benefits from momentum in its diversified pipeline including cancer candidates.
- Relative performance highlights trade-offs between CRSP’s long-term therapeutic potential and MRNA’s nearer-term revenue visibility from established platforms.
- Market positioning favors MRNA for short-term trend consistency in 2026, though both stocks exhibit sensitivity to sector-wide sentiment shifts.
Introduction
CRISPR Therapeutics (CRSP) and Moderna (MRNA) represent distinct approaches within the biotechnology sector, making them relevant for investors and traders seeking exposure to innovative therapeutic platforms. CRSP leverages gene-editing technology, whereas MRNA focuses on messenger RNA applications across infectious diseases and oncology. This comparison appeals to those evaluating growth-oriented biotech names, particularly participants monitoring relative performance, pipeline progress, and sector rotation in a dynamic market environment. The analysis examines observable business models, recent price behavior, and positioning factors without projecting outcomes.
CRSP Overview and Recent Performance
CRISPR Therapeutics (CRSP) develops CRISPR/Cas9 gene-editing therapies targeting conditions such as sickle cell disease and beta-thalassemia. In recent weeks, the stock has traded in a range near $46-47 following periods of consolidation, with notable declines observed amid mixed broader market conditions for biotech equities. Performance has reflected ongoing challenges in commercializing early therapies and general sector headwinds, though analyst coverage continues to highlight substantial long-term revenue growth potential from the pipeline. Sentiment has been influenced by clinical milestones and macroeconomic factors affecting high-valuation growth stocks.
MRNA Overview and Recent Performance
Moderna (MRNA) utilizes mRNA technology to develop vaccines and therapeutics, with an established COVID-19 product alongside expanding oncology and other pipeline programs. The stock has delivered robust year-to-date appreciation in 2026, though recent sessions featured pullbacks ahead of the upcoming earnings release. Volatility stems from shifting investor focus toward pipeline catalysts and evolving demand dynamics. Recent market activity shows resilience in longer-term momentum despite short-term fluctuations, supported by board enhancements and ongoing clinical readouts in cancer applications.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed for copy trading across stocks, ETFs, and crypto. The platform features hundreds of AI Trading Bots that trade thousands of different tickers, employing varied strategies, timeframes, and risk parameters. Only the strongest performers suited to prevailing market conditions earn placement in the Trending AI Robots section, which currently highlights 25 top bots selected from a total of 351 available. These bots differ in analytical approaches, performance statistics, and asset focus, allowing users to match preferences to individual trading styles. For further details on the latest trending options, visit Trending AI Robots.
Head-to-Head Comparison
CRISPR Therapeutics (CRSP) and Moderna (MRNA) diverge in core business models, with CRSP centered on precise gene editing and MRNA on scalable mRNA platforms. Growth drivers contrast accordingly: CRSP depends on advancing rare-disease therapies through clinical stages, while MRNA benefits from broader applications including respiratory vaccines and personalized cancer treatments. Recent momentum favors MRNA’s year-to-date trajectory, whereas CRSP has faced more pronounced near-term pressure. Risk factors include shared biotech elements such as trial outcomes and regulatory approvals, yet MRNA carries additional exposure to product demand cycles. Sector sentiment influences both, though MRNA’s established revenue base provides relative stability compared with CRSP’s earlier-stage profile.
Tickeron AI Verdict
Based on observable trend consistency and recent relative positioning, Tickeron’s AI would currently lean toward Moderna (MRNA) with moderate probability. The stock’s stronger year-to-date performance and proximity to key catalysts such as earnings contribute to this assessment, though CRSP retains appeal for investors prioritizing longer-horizon gene-editing opportunities. This evaluation reflects data patterns rather than certainty and should be considered alongside individual risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and MRNA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).
- CRSP’s FA Score: 0 green, 5 red.
- MRNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 5 TA indicator(s) are bullish while MRNA’s TA Score has 4 bullish TA indicator(s).
- CRSP’s TA Score: 5 bullish, 5 bearish.
- MRNA’s TA Score: 4 bullish, 6 bearish.
Price Growth
CRSP (@Biotechnology) experienced а +6.61% price change this week, while MRNA (@Biotechnology) price change was -7.01% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.94%. For the same industry, the average monthly price growth was +0.31%, and the average quarterly price growth was +2915.40%.
Reported Earning Dates
CRSP is expected to report earnings on Aug 10, 2026.
MRNA is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (+6.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CRSP | MRNA | CRSP / MRNA | |
| Capitalization | 5.18B | 23.6B | 22% |
| EBITDA | -627.33M | -2.8B | 22% |
| Gain YTD | -1.526 | 82.638 | -2% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 1M | 2.21B | 0% |
| Total Cash | 2.44B | 5.14B | 48% |
| Total Debt | 788M | 1.29B | 61% |
CRSP | MRNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 62 | 50 | |
P/E GROWTH RATING 1..100 | 78 | 3 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (78) in the Biotechnology industry is in the same range as MRNA (79). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRNA (100). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.
CRSP's SMR Rating (98) in the Biotechnology industry is in the same range as MRNA (99). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's Price Growth Rating (50) in the Biotechnology industry is in the same range as CRSP (62). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.
MRNA's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for CRSP (78). This means that MRNA’s stock grew significantly faster than CRSP’s over the last 12 months.
| CRSP | MRNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 79% | 5 days ago 79% |
| Declines ODDS (%) | 3 days ago 82% | 3 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 90% | 5 days ago 90% |
| Aroon ODDS (%) | 2 days ago 80% | 2 days ago 84% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AOK | 41.28 | -0.08 | -0.19% |
| iShares Core 30/70 Cnsrv Allc ETF | |||
| THMZ | 34.88 | -0.07 | -0.19% |
| Lazard Equity Megatrends ETF | |||
| USIG | 50.32 | -0.13 | -0.26% |
| iShares Broad USD Invm Grd Corp Bd ETF | |||
| NVDB | 32.59 | -0.14 | -0.43% |
| ProShares Ultra NVDA | |||
| AVSE | 77.12 | -0.47 | -0.61% |
| Avantis Responsible Emerging Mkts Eq ETF | |||